Asia Pacific Cephalosporin Drugs Market By Generation (First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin) By Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others) By Route of Administration (Injections and Oral Drugs) By Type (Branded and Generic)
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Cephalosporin Drugs Market
The Asia Pacific Cephalosporin Drugs Market would witness market growth of 2.73% CAGR during the forecast period (2019-2025).
Growth in population incidence with pneumonia, tonsillitis, bronchitis, and gonorrhea drives market growth. Increased R&D activities are expected to create extremely effective & secure medicines, increased use of combination therapies boost market development, and increased pneumonia, tonsillitis, bronchitis, & gonorrhea occurrence. These aforementioned factors help in accelerating the share of the global Cephalosporin Drugs market.
Manufacturers are engaged in the creation of new anti-microbial resistance drugs. The resistance mechanism has described the complexity and variety of the need for new and enhanced ?-lactam antibiotics. The firms are also engaged in the strategic growth of new products, such as Shionogi & Co in 2017. Ltd has been working with the F. Hoffmann-La Roche Ltd to develop and commercialize baloxavir marboxi.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Cephalosporin Drugs Market Analysis
- First-Generation Cephalosporin
- Second-Generation Cephalosporin
- Third-Generation Cephalosporin
- Fourth-Generation Cephalosporin
- Fifth-Generation Cephalosporin
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Sexually Transmitted Infection
By Route of Administration
- Oral Drugs
- South Korea
- Rest of Asia Pacific
- ABBOTT Laboratories
- Teva Pharmaceuticals Industries Ltd.
- Johnson and Johnson
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Merck & Co., Inc.
- Bayer AG
- Baxter International, Inc.
- BRISTOL-MYERS SQUIBB COMPANY
- Novartis AG
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free